National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, P.R. China.
The Third Hospital of Jilin University, Jilin University, Changchun 130012, P.R. China.
Immunol Lett. 2018 Jun;198:26-32. doi: 10.1016/j.imlet.2018.03.012. Epub 2018 Mar 27.
Pertussis, or whooping cough, has recently reemerged as a major public health threat despite high levels of vaccination. The development of a novel pertussis vaccine, especially an intranasal (i.n.) vaccine is undoubtedly necessary, and mucosal adjuvants have been explored to enhance the immune response. In the present study, bacterium-like particles (BLPs) were adopted as a mucosal adjuvant for an i.n. pertussis vaccine and evaluated on the ability to induce serum and mucosal antibodies as well as potency against i.n. challenge in mice. Groups with or without aluminum adjuvant were also evaluated through both i.n. and intraperitoneal inoculations. Vaccination with BLPs via the i.n. route led to rapid IgG and IgA production and provided strong protection against inflammation induced by infection. The results support an i.n. pertussis vaccine with BLPs adjuvant as a promising candidate to elicit protective immunity against whooping cough.
百日咳（或译白喉、哮吼），尽管疫苗接种率很高，但最近又重新成为一个主要的公共卫生威胁。开发新型百日咳疫苗，特别是鼻内（i.n.）疫苗无疑是必要的，并且已经探索了黏膜佐剂来增强免疫反应。在本研究中，类细菌颗粒（BLPs）被用作鼻内百日咳疫苗的黏膜佐剂，并评估了其诱导血清和黏膜抗体的能力以及对小鼠鼻内攻击的效力。还通过鼻内和腹腔接种评估了有或没有铝佐剂的组。通过鼻内途径接种 BLPs 可迅速产生 IgG 和 IgA，并对感染引起的炎症提供强有力的保护。结果支持使用 BLPs 作为鼻内百日咳疫苗佐剂，作为引起抗百日咳保护性免疫的有前途的候选物。
